Table 5 Clinical Characteristics and the Risk of Progression of CAC (among those RA patients with Detectable CAC at baseline)
Demographics | B (95% CI) | Adjusted B a (95% CI) |
|---|---|---|
  Age, years | -0.3 (-0.6, 1.3) | NA |
  Male sex | 8.3 (-8.1, 24.6) | NA |
  Caucasian race; number (%) | 28.0 (2.2, 53.7) | NA |
  Education; number (%) | -2.8 (-22.1, 16.5) | -2.3 (-24.3, 19.7) |
   Some college or higher |  |  |
Cardiovascular Risk Factors | Â | Â |
  Diabetes; number (%) | -6.5 (-32.5, 19.5) | 9.8 (-18.8, 38.4) |
  Hypertension (%) | 13.1 (-2.3, 28.6) | 5.4 (-14.6, 25.5) |
   Systolic BP, mm Hg | -0.3 (-0.8, 0.2) | -0.2 (-0.8, 0.4) |
   Diastolic BP, mm Hg | 0.1 (-0.8, 1.0) | 0.1 (-1.0, 1.2) |
  Dyslipidemia (%) | 16.7 (-1.2, 34.6) | 14.0 (-4.8, 32.8) |
   Total cholesterol, mg/dL | -0.1 (-0.3, 0.1) | -0.0 (-0.3, 0.2) |
   LDL cholesterol, mg/dL | 0.0 (-0.3, 0.2) | 0.1 (-0.3, 0.4) |
   HDL cholesterol, mg/dL | -0.1 (-0.4, 0.4) | 0.2 (-0.4, 0.9) |
   Triglycerides, mg/dL | -0.03 (-0.1, 0.0) | -0.1 (-0.2, 0.0) |
  Cigarette Smoking |  |  |
   Current; number (%) | 19. 9 (-5.7, 45.5) | 10.8 (-19.5, 41.2) |
Serum inflammatory markers at baseline | Â | Â |
  CRP, mg/L; median (IQR) | 3.2 (-3.5, 9.9) | 4.4 (-3.0, 11.7) |
  IL-6, pg/mL; median (IQR) | -1.8 (-11.4, 7.8) | -0.8 (-11.4, 9.9) |
  Fibrinogen, mg/dL; median (IQR) | 19.0 (-10.6, 48.5) | 13.9 (-20.0, 47.8) |
Disease characteristics at baseline | Â | Â |
  Disease duration (years) | 0.4 (-0.4, 1.2) | 0.6 (-0.28, 1.5) |
  RF | 3.9 (-13.2, 21.0) | 7.0 (-11.6, 25.6) |
  Anti-CCP | 4.2 (-15.9, 24.4) | -1.5 (-25.5, 22.5) |
  SE | 2.2 (-16.2, 20.6) | -6.8 (-27.8, 14.3) |
  DAS28 | 5.1 (-2.4, 12.7) | 6.5 (-1.5, 14.5) |
  HAQ | -5.1 (-17.6, 7.4) | -0.8 (-16.5, 14.9) |
  Sharp score | -0.0 (- 0.1, 0.1) | -0.0 (-0.1, 0.1) |
  Current use of MTX | -2.9 (-19.6, 13.7) | -3.2 (-17.9, 23.2) |
  Current use of biologic agents | 15.8 (-1.5, 33.0) | 18.5 (-1.4, 38.4) |
  Current use of corticosteroids | -8.6 (-25.8, 8.1) | -5.3 (-26.1, 15.3) |
  Disease characteristics, expressed as average over follow-up |  |  |
  DAS28 | 2.0 (-7.6, 11.6) | 4.8 (-6.0, 15.5) |
  CRP | -3.9 (-11.2, 3.5) | -1.1 (-9.7, 7.5) |
  IL-6 | -5.4 (-13.6, 2.9) | -6.0 (-16, 4.0) |
  Fibrinogen pg/mL; median (IQR) | -7.3 (-45, 29) | -6.1 (-50, 38) |